Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018
|
|
- Shana Sims
- 5 years ago
- Views:
Transcription
1 10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end of this session, the participant should be able to: 1. Discuss the epidemiology and natural history of HCV in Canada 2. Describe which persons should be screened for HCV 3. Discuss benefits, options and outcomes of therapy 4. Understand what to include in a specialist referral 5. Discuss any controversies and myths around HCV screening and treatment Five Take Home Pearls 1. Screen patients more liberally for Hepatitis including birth cohort born between Hepatitis C is curable in % of patients. 3. Curing HCV infection prevents progression to cirrhosis, improves symptoms and has mortality benefit. 4. Treatment is very well tolerated and fully publically funded for all patients with Hepatitis C. 5. If you need help consider referring to an ID or Hepatology specialist to help you cure your patient. Hepatitis C: Screen, Diagnose, Refer Screen Birth between 1945 and 1975 Any history of injection drug use Immigrants (excluding North America and Western Europe) Received blood transfusions, blood products, or organ transplant before 1992 in Canada High-risk sexual behaviour Test and Diagnose Test for anti-hcv antibody (indicates exposure to HCV) If positive Test for HCV RNA (genotype and baseline viral load) If positive Link to specialist care Link to Specialist Care Refer patient to HCV specialist treater Counsel patient (discuss implications of HCV infections, how to avoid transmission, need for alcohol elimination, importance of seeing an HCV specialist) We Can Cure Hepatitis C Infectious diseases we can t cure HIV Hepatitis B Herpes Human papillomavirus Infectious diseases we can cure Hepatitis C Syphilis Gonorrhea Chlamydia Trichomoniasis New Canadian Guidelines Birth Cohort Screening CMAJ June, 2018 Recommends that screening be both risk-based and target the birth cohort of individuals born from 1945 to Encompasses the majority of persons chronically infected with HCV in Canada (class of recommendation: 2a; level of evidence: C). HIV, human immunodeficiency virus. 1
2 Patient survival outcomes with and without SVR Cirrhosis (%) 10/15/2018 HCV and Alcohol: Risk of Cirrhosis Years Following Exposure HCV HCV + alcohol -Excessive alcohol intake characterized as > 40 g/day for women and > 60 g/day for men. -Studies suggest >50% of patients with HCV abuse alcohol Wiley TE, et al. Hepatology 1998:28: Viral Eradication Improves All-cause Mortality Criteria to Screen for HCV: Symptoms Fatigue Nausea, loss of appetite Arthralgia Abdominal pain Hepatosplenomegaly BUT 60-75% of patients are asymptomatic Cure = sustained virological response (SVR) = reduced risk of all-cause mortality; liver-related mortality; HCV-related complications; progression to HCC or liver failure 4 Possible dermatological signs: Mixed essential cryoglobulinemia Lichen planus Porphyria cutanea tarda Maculopapular rash Jaundice (past or present) Other possible extrahepatic manifestations: Membranous or membranoproliferative glomerulonephritis Non-Hodgkin s lymphoma Sjögren s syndrome 1. Ravazi 2012; 2. Burra 2009; 3. Guillouche 2011; 4. Van der Meer Virological tests to diagnose and confirm HCV infection Anti-HCV HCV-RNA HCV genotype Other bloodwork CBC Liver enzyme & function tests: ALT, AST, GGT, ALP, bilirubin, INR, albumin Normal ALT is not a contraindication to treatment (⅓ have normal test results) Creatinine Evaluation: Laboratory Testing Abdominal ultrasound Evaluate for cirrhosis and exclude HCC Tests to rule out coinfections Hepatitis A (HAV-Ab) Hepatitis B (HBsAg, HBsAb, HBcAb) HIV (Anti-HIV) DAA Regimens These regimens are all oral, varies between one to a few pills daily Treatment course 8-12 weeks Cure Rate %, based on genotype Well tolerated: in registration studies, have similar side-effects to placebo groups Need to review for drug-drug interactions, as can vary considerably between regimens Publically Funded. No cost to the patients!!!! 2
3 10/15/2018 Potential Drug-Drug Interactions & Monitoring of Labs Number of agents do have Drug-Drug interactions which requires the prescriber to either hold conmeds or select a regimen for HCV infection Rx that is appropriate. Very little monitoring is required while on therapy except in patients who have decompensated cirrhosis and especially if on ribavirin, which may be indicated with those who have cirrhosis and genotype 3 Hepatitis C in 2018 There is now a cure for this infectious disease. Pharmacare now funds treatment for all patients who have HCV infection regardless of the patients stage of disease. More medications are going to be available which will decrease the cost per patient. Nursing clinics help patients and physicians navigate the labyrinth of administrative work, provides education to patients and ensures patient adherence as well as emotional support. Referral Who should be referred? All persons HCV RNA (+) Role of staging by GP: AST to Platelet Ratio Index (APRI); Fibrosis-4 (FIB-4) Referral should include: HCV Genotype & RNA CBC (platelets important consideration) ALT, AST, ALP, GGT, bilirubin, INR, albumin ULTRASOUND Cirrhosis and Hepatocellular Carcinoma There is still an increased risk of developing HCC in patients with cirrhosis, even if they have been cured of HCV infection. Patients with cirrhosis will require q6 month ultrasound screening for HCC long term (life long?), if suspicious will need an MRI Patient Feedback after being Cured of HCV Infection % note significant increase in energy level All feel clean again or no longer feel dirty they are free of stigma Significant improvement in emotional well being Feel they can get on with their lives Thank You Questions and Discussion Contact Information Wayne Ghesquiere MD, FRCPC Infectious Diseases and Internal Medicine Consultant 1964 Fort St, Suite 206, Victoria, BC Tel , Fax
4 Hepatitis C Infection: Screening and Management for Compliments of By Wayne Ghesquiere MD, FRCP(C) Infectious Diseases and Internal Medicine Consultant 1964 Fort St, Suite 206, Victoria, BC Tel , Fax Consider screening your patient for Hepatitis C if he/she has any of the following: Baby Boomers i.e. born between should be screened at least once in their life time Any prior history of IV drug use or snorting cocaine Has received blood products prior to 1992 Born or raised in a developing country Has tattoos or body piercing Persistently elevated ALT or AST or has thrombocytopenia Steps to take if you are considering screening for Hep C: Step 1 Hepatitis C antibody serology. If this is positive this simply demonstrates the patient was exposed sometime in the past, you will then need to confirm if the patient is still infected. If it is positive then move on to step 2. If negative then reassure the patient. Step 2 Hepatitis C RNA and genotyping. If it s positive move onto step 3. If it is negative repeat 3 to 6 months later. If it remands negative then reassure the patient. Step 3 Blood work o CBC, differential, platelets, INR and PTT o Liver enzymes ALT, AST, Alkaline Phosphatase, GGT, T Bili, Albumin o Creatinine, GFR, Fasting Blood Sugar, Ferritin o Alpha Feto Protein level o Serology for Hepatitis A, B and HIV Abdominal Ultrasound Move onto step 4 Step 4 Consider a referral to a clinician who has an interest in further investigation and the management of the treatment of Hepatitis C infection i.e. Infectious Diseases consultant or Gastro/Hepatologist The patient must be free of alcohol abuse or active IVDU drug use for at least 3-6 months before they are considered for treatment. Key Points 1. Remember that people with normal liver enzyme levels can have advanced liver disease. A fibroscan or a liver biopsy is the only reliable way to assess the stage of disease i.e. fibrosis. 2. The risk of cirrhosis and liver cancer increases as the disease progresses. 3. Studies have repeatedly shown that early treatment provides a greater likelihood of cure than waiting until the disease is more advanced
5 Treatment Summary of Hepatitis C Treatment of Chronic Hepatitis C infection continues to evolve rapidly. Here is a list of medications that have recently been licensed in Canada for treatment of HCV and are available. The first 4 are available in BC under pharmacare coverage. The 5 th is available with third party coverage but soon will also be covered by pharmacare. Harvoni Zepatier Epclusa Vosevi Mavyret These are oral agents. Interferon is no longer required. These oral agents are remarkably well tolerated. Usually there are little to no side-effects. The success rate of treatment is based on both the genotype as well as the degree of liver disease i.e. amount of fibrosis. Fibrosis is confirmed and scored by way of either a FibroScan or a liver biopsy. There are also non imaging test such as the FIB-4 or APRI score that can be used to assess the degree of fibrosis but are less accurate. The more advanced the liver disease and fibrosis the lower the success rate. There are 6 different genotypes. The most common is genotype 1 (60% of Canadians have this type) followed by 2 and 3. Genotypes 4, 5 and 6 are less common in Canada. Occasionally Ribavirin is required. BC Pharmacare has approved and covers most of these agents. Many other provinces in Canada have done likewise. There are guidelines outlining who qualifies for treatment for Hepatitis C infection. Treatment is also tailored according to the patient s genotype and degree of fibrosis with duration of treatment anywhere between 8-12 weeks. The Cure Rates of Hepatitis C based on Genotyping and Fibrosis: Genotype 1 Stage 1-2 fibrosis ~ 98-99% Stage 3 fibrosis ~ 95-98% Stage 4 fibrosis (cirrhosis) ~ 95-98% Genotype 2 ~ 98-99% Genotype 3 ~ 95-99% Genotype 4 -Similar to genotype 1 Criteria for HCV Infection Therapy BC has liberalized the criteria for Hepatitis C therapy as of All patients with HCV infection qualify for treatment, regardless of their fibrosis staging. BC Pharmacare has restricted physicians who can order treatment to either infectious diseases physicians, gastroenterologists or other physicians who have demonstrated experience with HCV management and therapy. Special authority forms are still required to access these agents.
6 Chronic Hepatitis B Infection 2018: How to Investigate, Sort out Serology and When to Refer Compliments of By Wayne Ghesquiere MD, FRCP(C) Infectious Diseases and Internal Medicine Consultant 1964 Fort St, Suite 206, Victoria, BC Tel , Fax Chronic hepatitis B infection continues to be a significant problem despite the universal vaccination program which has been in place in BC and Canada since the early 1990 s. Both immigrants and non-immigrants are being diagnosed with hepatitis B infection regularly. If Hepatitis B is left unchecked, this infection can lead to cirrhosis, liver failure and hepatocellular carcinoma. Consider screening your patient for Hepatitis B virus if he/she has any of the following risk factors: Foreign born or raised in Asia, Pacific Islands, Africa, Middle East, Eastern Europe Parents or sexual partners who have Hepatitis B infection Has tattoos or body piercing Persistently elevated ALT or AST. Thrombocytopenia, lymphopenia Has positive serology for HIV, Hepatitis C or STI s Cirrhosis, ascites or a liver tumor Any past history of IVDU or snorting cocaine Steps to take if you are considering screening for Hep B: Step 1: Serology: Hepatitis B surface antigen (indicative of persistent infection) Hepatitis B surface antibody (indicative of immunity to the Hep B virus) Hepatitis B core antibody (Indicates prior exposure to the Hep B virus in the past) Step 2: If Hepatitis B surface antigen is positive the following investigations are recommended: Hepatitis B DNA titre Hepatitis B e antigen and e antibody CBC, diff, INR Creatinine, Blood sugar, ALT, AST, GGT, T Bilirubin, Albumin Alpha-feto Protein Serology for Hep A, C and HIV Abdominal Ultrasound FibroScan (This will be ordered by the consultant if it is considered necessary) See below.
7 Step 3: Treatment and referral being considered: Indication for referral would be any patient who has chronic Hepatitis B infection and a positive Hepatitis B DNA or elevated ALT Consider a referral to a clinician who has an interest in further investigation and the management of the treatment of Hepatitis B infection i.e. Infectious Diseases consultant or Gastro/Hepatologist. Positive Hep B DNA and increase ALT s are criteria for treatment. The patient must be free of alcohol or continued IVDU drug use for at least 6 months before they are ever considered for treatment. Treatment (often simply a once a day oral tablet which is covered by Pharmacare) is available to reduce the Hep B DNA to undetectable with normalization of ALT. Treatment also results in reversal of liver fibrosis. Step 4: Prevention measures and long term follow-up: Vaccinate family members, household contacts and sexual partners to Hepatitis B virus. Consider vaccinating the patient for Hepatitis A if they are Hepatitis A IgG negative. Patient will need lifelong screening for cirrhosis and hepatocellular carcinoma with abdominal ultrasound yearly and CBC, diff, INR, ALT, alpha-feto protein and Hepatitis B DNA titres every 4-6 months. Treatment Options Lamivudine Adefovir Entecavir Tenofovir (TDA) Tenofovir (TAF) Unfortunately Pharmacare requires patients to start with lamivudine. If it fails (which it does in 60-70% of the time) then patients can access Tenofovir which is far more effective. The good news is Tenofovir is now generic hence often patients will opt for that choice. What is a FibroScan? A FibroScan is a non-invasive imaging study that evaluates the degree of liver stiffness, or scaring, known as fibrosis. FibroScan has a 90% accuracy, it takes minutes to perform and is painless. The results of the study do need to be used in conjunction with the history, physical examination and lab data by a physician trained to interpret the results. The wait time for this study is only a few weeks to months. A FibroScan can be requested by infectious diseases, gastroenterology, internal medicine consultant or physicians with extensive experience in liver diseases The scanner has been useful to determine the degree of fibrosis in patients with, Hepatitis B, Hepatitis C, HIV/Hepatitis C co-infection, Alcohol liver disease and NAFLD In certain patients with liver disease it does not replace the need for a liver biopsy which helps to establish a diagnosis
8 Key Take Home Pearls Hepatitis C Screen patients more liberally for Hepatitis C infection (and hepatitis B). Birth cohort years especially. 2. Hepatitis C infection is curable in 95-99% of patients. 3. Curing the patient of HCV infection prevents cirrhosis, improves symptoms and reduces mortality. 4. Treatment is very well tolerated and is publically funded. As of 2018 all patients with HCV infection will are eligible for treatment in BC. 5. Refer to an Infectious Diseases or Hepatology specialist to help you cure your patient. Encourage your patients to seek advice.
9 HEPATITIS B SEROLOGY Hepatitis B surface antigen (HBsAg): A protein on the surface of the hepatitis B virus (HBV); It can be detected in high levels in serum during acute or chronic HBV infection. The presence of HBsAg indicates that the person is infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. HBsAg is the antigen used to make Hepatitis B vaccine. Hepatitis B surface antibody (anti-hbs): The presence of anti-hbs is generally interpreted as indicating recovery and immunity from HBV infection. Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B. Total hepatitis B core antibody (anti-hbc): Appears at the onset of symptoms in acute hepatitis B infection and persists for life. The presence of anti-hbc indicates previous or ongoing infection with HBV in an undefined time frame. IgM antibody to hepatitis B core antigen (IgM anti-hbc): Positivity indicates recent infection with HBV ( 6 months). Its presence usually indicates acute infection. Hepatitis B e antigen (HBeAg): A secreted product of the nucleocapsid gene of the hepatitis B virus that is found in serum during acute and chronic hepatitis B infection. Its presence indicates that the virus is replicating and the infected person has high levels of HBV. Hepatitis B e antibody (HBeAb or anti-hbe): Produced by the immune system temporarily during acute HBV infection or consistently during or after a burst in viral replication. Spontaneous conversion from e antigen to e antibody (a change known as seroconversion) is a predictor of long-term clearance of HBV in patients undergoing antiviral therapy and indicates lower levels of HBV.
10 Hepatitis B: Frequently Asked Questions about Serology and the HBV Vaccine 1) You have a patient who is positive for anti-hbc (hepatitis B core antibody) but negative for all other hepatitis B serologic markers. Should he receive hepatitis B vaccine? Some isolated positive anti-hbc results are false positives (it is the most common false positive HBV marker). If that can be established, the individual can and likely should be vaccinated, assuming there is an indication or desire to be protected. If the positive anti-hbc is believed to be a true positive, the individual would not require vaccination since they have already (presumably) had HBV infection. They do not need HBV treatment either unless they go onto immunosuppressive therapy in the future. 2) You come across a hepatitis B panel for a new hospital employee from Ethiopia. She had no documentation of having been vaccinated. Her results showed HBsAg nonreactive, anti-hbc reactive, IgM anti-hbc nonreactive, and anti-hbs borderline. We don t know how to interpret these results. Should she be immunized? Most likely this person has a resolved hepatitis B infection and is immune. However, it would be preferable to test her again for all these serologic markers, and also quantify the anti-hbs result. If the results are still positive for anti-hbc, and anti-hbs is less than the immune level of 10mIU/mL, you can give her one dose of hepatitis B vaccine and test again in 1 2 months. If the anti-hbs is positive (10 miu/ml or higher), she is immune. No further action is needed other than to document the results. If the anti-hbs is still negative, complete the vaccine series and test again 1 2 months after the last dose of vaccine. If she is still anti-hbs negative after 3 doses of vaccine, test again for HBsAg to be sure she is not chronically infected (unlikely) and counsel her as a non-responder. 3) How long is hepatitis B vaccine protective? Studies indicate that immunologic memory remains intact for at least 20 years and confers protection against clinical illness and chronic HBV infection, even though anti-hbs levels that once measured adequate might become low or decline below detectable levels. If one is challenged with HBV, people whose immune systems are competent will mount an anamnestic response and develop protective anti-hbs. Studies are ongoing to assess whether booster doses of hepatitis B vaccine will be needed in the future. At this point it s considered the vaccine is good for life. 4) An adolescent received the first dose of hepatitis B vaccine at age 11 years but did not return for subsequent doses at school. If the patient comes back at age 18 years, is it necessary to repeat the first dose of the series? It is not necessary to restart or add doses to the hepatitis B series (or any other routine vaccine series including Hepatitis A) because of a prolonged interval between doses. Just continue the series from the point where it was interrupted. The same holds true for an adult. 5) Is post-vaccination testing needed for adults who receive hepatitis B vaccine? Serologic testing for immunity after vaccination is recommended only for people whose subsequent clinical management depends on knowledge of their immune status. Testing is not necessary after routine vaccination of adults. Post-vaccination testing is recommended for the following: healthcare and public safety workers at a reasonable risk of continued exposure to blood on the job; immune compromised people; and sex or needle-
11 sharing partners of HBsAg-positive people. Testing should be performed 1 to 2 months after the last dose of vaccine. 6) What about the need for testing if the hepatitis B vaccine series was completed many years ago. All healthcare personnel (HCP) with risk of exposure to hepatitis B should be tested 1 to 2 months after receiving the third dose of hepatitis B vaccine. Health Canada does not recommend testing healthcare personnel who were not tested within the 1 to 2 month post vaccination time frame. HCP who are exposed to Hepatitis B can be tested as part of post exposure management, if indicated. 7) A patient who is certain they had three doses of the Hep B vaccine in the past (but did not get tested for anti-hbs 1-2 months later) is found to be anti HBs negative. What should be done about the vaccine? If the test was not done after a high risk exposure you could give them 1 single adult dose of the Hep B vaccine and test their anti-hbs titre 1 month later. If it s positive you can now say they have been boosted and are immune. If it s negative you can have them finish the 3 dose series. Test them 1-2 months later. If the anti- HBs is positive then document they responded. It it s still negative they can be considered a non-responder. 8) In what situation should routine screening for anti-hbs and HBsAg be performed for HBV? The following would require the screen: high risk exposure to HBV (current STI s, MSM, active IVDU, sexual partners or household contacts of patients with positive HBSAg, sexual assault, needle stick injury), entering training or starting a new job as a HCW or a medical lab, about to undergo immunosuppression therapy, prenatal screening, patients about to start hemodialysis, patients with chronic liver disease, HIV infection, residents and staff of facilities caring for the developmentally challenged, those working in corrections facilities, immigrants (especially those born in Asia, Pacific Island, Africa) and refugees. 9) You ve identified a patient in your obstetrical practice who is HBsAg positive. Should she be evaluated for liver disease during her pregnancy, or should the evaluation wait until the postpartum period? What should you recommend for her husband and her children? How urgent is the time frame? The earlier the evaluation is done, the better. Consultation with or referral to a liver disease specialist (such as an infectious diseases specialist or Hepatologist,) should be done. The consulting/referral physician should be completely aware of the patient's obstetrical status. In addition, the patient's sex partner and children or other household contacts should be tested for HBV infection (total anti-hbc and HBsAg) as soon as possible. If any are susceptible to HBV infection (total anti-hbc and HBsAg negative), they should be vaccinated. If any are HBsAg positive, they should be referred to or have consultation with an infectious diseases or liver disease specialist. The newborn baby at time of delivery will need HBIG and initiation of the HBV vaccine series. 10) How often should you test HCW after they've received the hepatitis B vaccine series to make sure they're protected? For immunocompetent HCW, periodic testing or periodic boosting is not needed. Post-vaccination testing (anti-hbs) should be done 1 2 months after the last dose of the hepatitis B vaccine series. If adequate anti- HBs (at least 10 miu/ml) is present, nothing more needs to be done. This information should be made available to the employee and recorded in the employee's health record. If post-vaccination testing is less than 10 miu/ml, the 3-dose vaccine series should be repeated and anti-hbs testing done, 1 2 months after the last dose of the second series. If they are still less than 10mIU they are considered a non-responder and at risk of HBV infection. They should be counselled and take appropriate precautions.
Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives
On the Liver Disease Front Lines: Hepatitis A, B and C Prevention and Treatment Kurt Cook, MD, MSc ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family
More informationThe Hepatitis B-e antigen-positive
The Hepatitis B-e antigen-positive Dental Student Developing an Equitable Policy Hepatitis B Virus Serology 1 HBsAg A protein on the surface of HBV; it can be detected in high levels in serum during acute
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationX-Plain Hepatitis B Reference Summary
X-Plain Hepatitis B Reference Summary Introduction Hepatitis B is the most common serious liver infection. It is caused by the hepatitis B virus that attacks the liver. The virus is transmitted through
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationAssessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY
Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationC 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官
C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官 HCV:Structure and Classification Unclassified virus, Member of the flavivirus family (other members yellow fever and dengue) Enveloped single stranded RNA virus Humans
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationArvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine
Arvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine No financial disclosures No conflicts of interest No affiliations
More informationTHIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE
THIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE The following content is provided for informational purposes only. Diagnosing and Managing Hepatitis C Sandy Van Sant MPH, APN Hepatitis C virus
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationSandi Mitchell Nurse Educator Clinical Prevention Services BCCDC
Sandi Mitchell Nurse Educator Clinical Prevention Services BCCDC sandi.mitchell@bccdc.ca Hepatitis A, B and C Testing Transmission Treatment What Is Hepatitis? Hepatitis means inflammation of the liver
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
More informationElaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax
Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus 231-727-5575/231-728-4054 Fax » CURABLE» Most common blood borne infection» 75-85% of those exposed will develop chronic infection»
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationPart I. Prior Authorization Criteria and Policy
Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationDEPARTMENT OF GENITO-URINARY MEDICINE HEPATITIS B
DEPARTMENT OF GENITO-URINARY MEDICINE MAIN TRANSMISSION ROUTES HEPATITIS B Sexual transmission Occurs in unvaccinated/non immune men who have sex with men and correlates with multiple partners, unprotected
More informationThe Long Term Care Risk
Hepatitis C The Long Term Care Risk Objectives Basics of the disease Disease progression Comorbid factors Treatment Long term care risk Basics of Hepatitis C Caused by an RNA virus Clinical Course Acute
More informationABCs of Viral Hepatitis What Primary Care Physicians Need to Know
ABCs of Viral Hepatitis What Primary Care Physicians Need to Know Dr Kenny C.P. Sze Associate Consultant Division of Gastroenterology Department of General Medicine Outline and Keypoints Hepatitis A Recap;
More informationi Screening and Natural History
HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationViral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician
Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Outline: Virology HBV + pregnancy HCV + new treatments Cases Hepatitis Foundation HBV: virus HBsAg far in excess of complete virions,
More informationHepatitis A, B, and Mostly C
Hepatitis A, B, and Mostly C Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Leaning Objectives Burden of viral hepatitis Hepatitis A A little bit about hepatitis E Hepatitis B Hepatitis
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationReplaces: 04/14/16. Formulated: 8/2007 HEPATITIS C POLICY
Replaces: 04/14/16 Page 1 of 9 This policy is not intended to delineate all the aspects of the care of an offender with hepatitis C. In particular, the minimal requirements in this policy are intended
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationPRISONS Health Services Policies and Procedures
BACKGROUND NATURAL HISTORY OF CHRONIC HCV INFECTION Following infection with the hepatitis C virus (HCV), chronic infection typically occurs, with approximately 50 to 85 percent of cases developing chronic
More informationViral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN
Viral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN General Concepts Hepatitis = 'inflammation of the liver'. Virus causes: Hepatotropic and
More informationIsolated Hepatitis B Core Antibody
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014 Isolated Core Antibody Virology & terminology Definition
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES
ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More information2013 UPDATES IN HEPATITIS B & C
2013 UPDATES IN HEPATITIS B & C Jennifer C. Lai, MD, MBA Division of Gastroenterology/Hepatology University of California, San Francisco Financial disclosures: none Outline: HBV & HCV Case-based presentations
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationCurrent Issues in Hepatitis B and C
Current Issues in Hepatitis B and C Rena Fox, MD Professor of Clinical Medicine Division of General Internal Medicine May-June 2018 Disclosures: Quality improvement project funded by Gilead Sciences, completed
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationChronic hepatitis B virus (HBV)
Chronic hepatitis B virus (HBV) Information for patients This leaflet explains chronic hepatitis B virus, including how you may have become infected, the main symptoms and how it is treated. If you have
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationCommunity/GP based screening & management of HBV & HCV
Community/GP based screening & management of HBV & HCV Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationObstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School
Obstetric Complications in HIV-Infected Women Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School Obstetric Complications and HIV Obstetric complications are not increased in
More informationHCV Case Studies (and Special Populations)
HCV Case Studies (and Special Populations) Case 1: Alfred 58 y/o man presents to clinic for primary care f/u. PMH: Hypertension, diabetes Medications: lisinopril, glipizide Allergies: NKDA Family History:
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
More information